EUCTR2006-006693-24-FR进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects of 12 years of age or older.
- •2. Body mass index equal or above -2 SDS (Standard Deviation Score-According to CDC standards) for 12-19 year old patients and =18.5 kg/m2 for adults 20 years old and older.
- •3. Have a confirmed diagnosis of cystic fibrosis: positive sweat chloride value ³ 60 mEq/l by quantitative pilocarpine iontophoresis (on at least 2 occasions, if no genotype was determined) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype.
- •Measurement of nasal potential difference could be considered as an additional diagnostic tool, if results of sweat chloride test and genotype tests are not unambiguous. Nasal potential difference test can not replace any of the above tests and should not be interpreted in isolation.
- •4. Have Screening FEV1 between 50% and 85% of predicted.
- •5. Have oxygen saturation level measured by pulse oximetry (SpO2) > 90 % on room air.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Show bronchial hyperresponsiveness as known from previous visits e.g. the subject needs additional puffs of salbutamol (or other beta-2-agonists) more than twice daily. This also applies to subjects who have shown bronchoconstriction to previously administered inhalation therapies or a decrease of FEV1 = 20% during or after administration of placebo at the screening visit.
- •2. Have shown any evidence for unstable lung function, e.g. have had more than 15% FEV1 variation (difference between highest and lowest measured value in % of highest value measured) in the last 3 months before treatment starts (i.e. visit 2).
- •3. Have a pulmonary disease such as pneumonia, tuberculosis, or lung cancer.
- •4. Have had an acute upper respiratory tract infection within the last 2 weeks.
- •5. Have had an acute lower respiratory tract infection (requiring antibiotics or hospitalization) within the last 4 weeks.
- •6. Have had an pulmonary exacerbation within the last 4 weeks.
- •7. Have had any changes from routine maintenance therapy within the last 4 weeks.
- •8. Have any scheduled changes to inhaled antibiotics regimen during the course of the study.
- •9. Receive or are planned to receive any treatment via on-off” regimen (e.g. Tobramycin – TOBI®)
- •10. Have received the last dose of any on-off” treatment within the last 6 weeks.
- •11. Have any clinically significant liver, renal, cardiac (as defined by QTc >450 msec (or 0.450 seconds) for males or QTc> 470 msec (or 0.470 seconds) for females), neurological, or hematological disease.
- •12. Have allergic bronchopulmonary aspergillosis or colonization with Burkholderia cepacia.
- •13. Have poorly controlled diabetes mellitus.
- •14. Have smoked more than 3 cigarettes per day within the last 12 months.
- •15. Have a history of alcohol (> 40g/day) or drug abuse.
- •16. Have participated in an investigational drug study (including Moli1901) within the last 8 weeks.
- •17. Are women of child bearing potential and refuse to use effective contraception or are pregnant or lactating.
- •18. Are unwilling to perform appropriate safe contraception for at least 6 months after investigational product administration.
研究者
相似试验
进行中（未招募）
1 期
Study to test the efficacy and safety of Padsevonil as adjunctive treatment of focal-onset seizures in adults with drug-resistant epilepsyFocal-Onset SeizuresMedDRA version: 20.0Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852EUCTR2017-003200-48-LTCB Biopharma SPR411
进行中（未招募）
不适用
A study to evaluate the efficacy of different doses of LY3009104 therapy compared to placebo in patients with Rheumatoid Arthritis who are on ongoing methotrexate background therapy.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-022504-42-HUEli Lilly and Company270
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart FailureHeart FailureEUCTR2013-002893-35-SKTrevena Inc.500
进行中（未招募）
1 期
This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of up to 70 weeks of treatment with tildacerfont in subjects with classic Congenital adrenal hyperplasia (CAH) who have elevated blood hormones at baselineClassic Congenital Adrenal HyperplasiaMedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850EUCTR2019-004764-22-PLSpruce Biosciences, Inc.72
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back PaiModerate to severe, chronic, low back pain (LBP) that is not adequately controlled by standard pain therapyMedDRA version: 9.1Level: LLTClassification code 10024891Term: Low back painEUCTR2009-009857-17-BEJanssen-Cilag International NV360